The Beijing Pregene Science and Technology Company, Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Beijing China (2014)
Status: Defunct (2020)

Organization Overview

First Clinical Trial
2016
NCT03101709
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

The Pregene (ShenZhen) Biotechnology Company, Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 6